PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
PMV Pharmaceuticals (Nasdaq: PMVP), a precision oncology company focused on p53-targeting therapies, has announced its participation in two major upcoming investor conferences. David H. Mack, Ph.D., President and CEO, and Deepika Jalota, Pharm. D., Chief Development Officer, will represent the company.
The conferences include the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, at 12:40 PM EST, and the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 3:10 PM EST. Management will also conduct one-on-one investor meetings during these events.
Live audio webcasts will be available online, with archived replays accessible for 90 days following each presentation through the company's Events & Presentations platform.
PMV Pharmaceuticals (Nasdaq: PMVP), un'azienda di oncologia di precisione focalizzata sulle terapie mirate al p53, ha annunciato la sua partecipazione a due importanti conferenze per investitori in arrivo. David H. Mack, Ph.D., Presidente e CEO, e Deepika Jalota, Pharm. D., Direttore Sviluppo, rappresenteranno l'azienda.
Le conferenze includono la 35ª Conferenza Annuale Oppenheimer sulle Scienze della Vita e della Salute il 12 febbraio 2025, alle 12:40 PM EST, e la 45ª Conferenza Annuale TD Cowen sulla Salute il 4 marzo 2025, alle 3:10 PM EST. La Direzione condurrà anche incontri individuali con gli investitori durante questi eventi.
Webcast audio dal vivo saranno disponibili online, con repliche archiviabili accessibili per 90 giorni dopo ogni presentazione attraverso la piattaforma Eventi & Presentazioni dell'azienda.
PMV Pharmaceuticals (Nasdaq: PMVP), una empresa de oncologÃa de precisión centrada en terapias dirigidas al p53, ha anunciado su participación en dos importantes conferencias para inversores que se aproximan. David H. Mack, Ph.D., Presidente y CEO, y Deepika Jalota, Pharm. D., Directora de Desarrollo, representarán a la empresa.
Las conferencias incluyen la 35ª Conferencia Anual Oppenheimer de Ciencias de la Salud el 12 de febrero de 2025, a las 12:40 PM EST, y la 45ª Conferencia Anual TD Cowen de Atención Médica el 4 de marzo de 2025, a las 3:10 PM EST. La dirección también llevará a cabo reuniones individuales con inversores durante estos eventos.
Se ofrecerán webcasts de audio en vivo en lÃnea, con repeticiones archivadas accesibles durante 90 dÃas después de cada presentación a través de la plataforma de Eventos & Presentaciones de la compañÃa.
PMV Pharmaceuticals (Nasdaq: PMVP)ëŠ� p53 표ì 치료ì—� 중ì ì� ë‘� ì •ë°€ 종양í•� 회사ë¡�, 다가오는 ë‘� ê°œì˜ ì£¼ìš” 투ìžìž� 회ì˜ì—� 참가í•� 것ì´ë¼ê³ 발표했습니다. David H. Mack, Ph.D. 사장 ê²� CEO와 Deepika Jalota, Pharm. D. 개발 ì±…ìž„ìžê°€ 회사ë¥� 대표합니다.
회ì˜ëŠ� 2025ë…� 2ì›� 12ì� ë™ë¶€ 표준ì‹� 기준 오후 12ì‹� 40ë¶„ì— ì—´ë¦¬ëŠ� 오펜하ì´ë¨� ì �35íš� ì—°ë¡€ ì˜ë£Œ ìƒëª… 과학 회ì˜ì™€ 2025ë…� 3ì›� 4ì� ë™ë¶€ 표준ì‹� 기준 오후 3ì‹� 10ë¶„ì— ì—´ë¦¬ëŠ� TD 코웬 ì �45íš� ì—°ë¡€ ê±´ê°• ê´€ë¦� 회ì˜ë¥� í¬í•¨í•©ë‹ˆë‹�. ê²½ì˜ì§„ì€ ì´ëŸ¬í•� ì´ë²¤íŠ� ë™ì•ˆ 투ìžìžì™€ì� ì¼ëŒ€ì� 회ì˜ë� 진행합니ë‹�.
온ë¼ì¸ì—ì„� ë¼ì´ë¸� 오디ì˜� 웹ìºìŠ¤íŠ¸ê°€ ì œê³µë˜ë©°, ê°� í”„ë ˆì í…Œì´ì…˜ 후ì—ëŠ� 회사ì� ì´ë²¤íŠ� & í”„ë ˆì í…Œì´ì…˜ 플랫í¼ì„ 통해 90ì� ë™ì•ˆ ì•„ì¹´ì´ë¸Œ 재ìƒì� 가능합니다.
PMV Pharmaceuticals (Nasdaq: PMVP), une entreprise de cancérologie de précision axée sur des thérapies ciblant le p53, a annoncé sa participation à deux grandes conférences d'investisseurs à venir. David H. Mack, Ph.D., Président et CEO, et Deepika Jalota, Pharm. D., Directrice du Développement, représenteront l'entreprise.
Les conférences incluent la 35e Conférence Annuelle Oppenheimer sur les Sciences de la Vie et de la Santé le 12 février 2025 à 12h40 EST, et la 45e Conférence Annuelle TD Cowen sur les Soins de Santé le 4 mars 2025 à 15h10 EST. La direction organisera également des réunions individuelles avec les investisseurs lors de ces événements.
Des webcasts audio en direct seront disponibles en ligne, avec des rediffusions archivées accessibles pendant 90 jours après chaque présentation via la plateforme Événements & Présentations de l'entreprise.
PMV Pharmaceuticals (Nasdaq: PMVP), ein Unternehmen für präzise Onkologie mit dem Fokus auf p53-zielgerichtete Therapien, hat seine Teilnahme an zwei wichtigen bevorstehenden Investorenkonferenzen bekannt gegeben. David H. Mack, Ph.D., Präsident und CEO, sowie Deepika Jalota, Pharm. D., Chief Development Officer, werden das Unternehmen vertreten.
Die Konferenzen umfassen die 35. jährliche Oppenheimer-Konferenz für Gesundheits- und Lebenswissenschaften am 12. Februar 2025 um 12:40 Uhr EST und die 45. jährliche TD Cowen Gesundheitskonferenz am 4. März 2025 um 15:10 Uhr EST. Das Management wird während dieser Veranstaltungen auch persönliche Investorenmeetings durchführen.
Live-Audio-Webcasts werden online verfügbar sein, mit archivierten Wiedergaben, die 90 Tage nach jeder Präsentation über die Event- & Präsentationsplattform des Unternehmens zugänglich sind.
- None.
- None.
PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences. Management will also participate in one-on-one investor meetings.
Oppenheimer 35th Annual Healthcare Life Sciences Conference
Date: Wednesday, February 12, 2025
Time: 12:40 PM EST
TD Cowen 45th Annual Health Care Conference
Date: Tuesday, March 4, 2025
Time: 3:10 PM EST
A live audio webcast of the events will be available online at . An archived replay of the events will be available for 90 days following the webcast at .
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. TP53 mutations are found in approximately half of all cancers. Our co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize more than four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus. PMV Pharma is headquartered in Princeton, New Jersey. For more information, please visit .
Investors Contact:
Tim Smith
Senior Vice President, Head of Corporate Development and Investor Relations
Media Contact:
Kathy Vincent
Greig Communications
